Read the entire Fraunhofer IPT press release issued 12 February 2019 here. Below is an excerpt from it.
Exploring commercial perspectives of the project outputs
The AUTOSTEM team which has been working together in the project represents a wealth of experience in regenerative medicine, automation and robotics, bio-reactors and cell production, regulatory affairs and quality control, over more than ten years. The project began on 1 January 2016 and finished successfully on 31 December 2018. Finally, the researchers have been biologically validating the cells that had been produced in the project in vitro and in vivo, in order to ensure the clinical-relevance of the product.
As the prototype of the AUTOSTEM platform has been finished now, more work will be needed to allow for direct clinical use in patients, so the next steps will be exploring the markets for the project outputs. New knowledge about MSC selection and expansion, bioreactor systems, sensor technology and MSC action has been gained, which will present opportunities for further research and collaboration.
“The project is paving the way towards the cost-effective manufacture of MSCs and other therapeutic cell products in the future. Ultimately, this will benefit patients, clinicians and health systems, yielding wider societal and economic benefits”, says Dr Mary Murphy of the National University of Ireland, Galway, Coordinator of the AUTOSTEM project.
Download the AUTOSTEM Platform brochure here.
For more information, please contact:
Jelena Ochs M.Sc.
Head of the business unit “Life sciences engineering”
Fraunhofer Institute for Production Technology IPT
52074 Aachen, Germany
Phone +49 241 8904-571
Fax +49 241 8904-6571